NCOG-29. THE NEURO-ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (NEURO-MCBS) AS A COMPREHENSIVE AND CLINICALLY RELEVANT ASSESSMENT TOOL TO DETERMINE CLINICAL BENEFIT FROM TARGETED THERAPIES IN CNS TUMORS
NCOG-29. 神经肿瘤临床获益程度量表(NEURO-MCBS)作为一种全面且具有临床意义的评估工具,用于确定中枢神经系统肿瘤靶向治疗的临床获益
期刊:Genomics
影响因子:3
doi:10.1016/j.ygeno.2020.10.032
Beer, Philip A; Cooke, Susanna L; Chang, David K; Biankin, Andrew V; Kurz, Sylvia C; Renovanz, Mirjam; Rieger, Johannes; Bombach, Paula; Grosse, Lucia; Rieger, David; Hucker, Svenja; Hille, Hanni; Hippler, Melina; Oener, Oeznur; Ruhm, Kristina; Beha, Janina; Malek, Holly S; Moeller, Yvonne; Bitzer, Michael; Malek, Nisar; Tabatabai, Ghazaleh